Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank

Characterisation of the natural history of myositis subgroups :responses to treatments, prognosis factors, evolution

Characterisation of the natural history of myositis subgroups :responses to treatments, prognosis factors, evolution

Time frame: up to twenty years after inclusion

Characterisation of an immune system signature, using peripheral blood mononuclear cells and muscular biopsies, DNA and RNA sequencing, and autoantibodies

Characterisation of an immune system signature, using peripheral blood mononuclear cells and muscular biopsies, DNA and RNA sequencing, and autoantibodies

Time frame: baseline: first 30 days after inclusion

Risk factors for All-cause mortality depending on patient's and disease characteristics

Risk factors for All-cause mortality depending on patient's and disease characteristics including clinical, radiological electrophysiological, histo-biological and immunological as well as treatment received stratified by each subgroup of myositis

Time frame: up to twenty years after inclusion

Change of the quality of life, using quality of life questionnaires, depending of patients and disease characteristics

Change of the quality of life, using quality of life questionnaires, depending of patients and disease characteristics (HAQ (Health Assessment Questionnaire)global health status scale (0-100))

Time frame: up to twenty years after inclusion

Change of activity impairment using an evaluation of daily life activity by both patient and physician using a Visual Analogue Scale depending of patients and disease characteristics

Using analogue Scale depending of patients and disease characteristics: Physician's assessment of disease activity in the muscle area (VAS 0-10) Physician's evaluation of the disease activity in the skin area (VAS 0-10) Physician's evaluation of general signs of disease activity (VAS 0-10) Physician's assessment of disease activity in rheumatology (VAS 0-10) Physician's assessment of disease activity in the digestive area (VAS 0-10) Physician's assessment of disease activity in the pulmonary area (VAS 0-10) Physician's assessment of disease activity in the cardiac area (VAS 0-10) Doctor's assessment of disease activity in the extra-muscular area (VAS 0-10) Overall evaluation of the disease activity (muscular and extra-muscular) by the PHYSICIAN (VAS 0-10) Global evaluation of the disease activity by the PATIENT (VAS 0-10)

Time frame: up to twenty years after inclusion

Characterisation of a quality-of-life scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements

Using MM8 testing (0-150) visceral involvements

Time frame: up to twenty years after inclusion

Characterisation of a global activity scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements

Using MM8 testing (0-150)

Time frame: up to twenty years after inclusion

Incidence of major cardio-vascular events

Incidence of major cardio-vascular events

Time frame: up to twenty years after inclusion

Consequences on outcomes of major cardio-vascular events

Major cardiovascular will include: * Heart failure * Myocardial infarction * Stroke * Sudden cardiac death * High-degree atrio-ventricular blocks * High-degree sinus dysfunction * Sustained ventricular tachycardia

Time frame: up to twenty years after inclusion

Correlation of myositis with the development of extra-muscular diseases including but not limited to dermatological, rheumatological, cardiological and pneumological associated diseases

Correlation of myositis with the development of extra-muscular diseases including but not limited to dermatological, rheumatological, cardiological and pneumological associated diseases

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using spirometry (Vital capacity in the sitting position)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in supine position)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (FEV1/VC ratio)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Total lung capacity by Plethysmographic)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Inspiratory capacity)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (maximum static inspiratory pressure as % of predicted value)

Time frame: up to twenty years after inclusion

Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Sniff nasal inspiratory pressure in % of predicted value)

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in the sitting position )

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry ( Vital capacity in supine position )

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (FEV1/VC ratio)

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Total lung capacity by Plethysmographic)

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Inspiratory capacity)

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (maximum static inspiratory pressure as % of predicted value)

Time frame: up to twenty years after inclusion

Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Sniff nasal inspiratory pressure in % of predicted value)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in supine position)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in the sitting position)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (FEV1/VC ratio)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Total lung capacity by Plethysmographic)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Inspiratory capacity)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (maximum static inspiratory pressure as % of predicted value)

Time frame: up to twenty years after inclusion

Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Sniff nasal inspiratory pressure in % of predicted value)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Sniff nasal inspiratory pressure in % of predicted value)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (maximum static inspiratory pressure as % of predicted value)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Inspiratory capacity)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Total lung capacity by Plethysmographic)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (FEV1/VC ratio)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in the sitting position)

Time frame: up to twenty years after inclusion

Follow up of diaphragmatic function with pulmonary function test and thoracic tomodensitometry

Using Spirometry (Vital capacity in supine position)

Time frame: up to twenty years after inclusion